Search results
Results from the WOW.Com Content Network
Cimetidine is widely distributed throughout all tissues. [7] It is able to cross the blood–brain barrier and can produce effects in the central nervous system (e.g., headaches, dizziness, somnolence). [2] The volume of distribution of cimetidine is 0.8 L/kg in adults and 1.2 to 2.1 L/kg in children. [6]
Cimetidine was the prototypical histamine H 2 receptor antagonist from which later drugs were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) by James W. Black, C. Robin Ganellin, and others to develop a histamine receptor antagonist that would suppress stomach acid secretion.
Ranitidine has 10% of the affinity that cimetidine has to CYP450, so it causes fewer side effects, but other H 2 blockers famotidine and nizatidine have no CYP450 significant interactions. [ 131 ] Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. [ 132 ]
Vasculitis [3] Alpidem (Ananxyl) 1995. Worldwide. Not approved in the US, withdrawn in France in 1994 [4] and the rest of the market in 1995 because of rare but serious hepatotoxicity. [3][5] Alosetron (Lotronex) 2000. US. Serious gastrointestinal adverse events; ischemic colitis; severe constipation. [2]
Famotidine, sold under the brand name Pepcid among others, is a histamine H 2 receptor antagonist medication that decreases stomach acid production. [4] It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. [4]
Charon Robin Ganellin FRS (born 25 January 1934) is a British medicinal chemist, and Emeritus Smith Kline and French Professor of Medicinal Chemistry, at University College London. [1][2] Ganellin has contributed much to the field of drug discovery and development. His most outstanding achievement was the discovery of cimetidine, a drug used to ...
Nizatidine is a histamine H 2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. [2] It was patented in 1980 and approved for medical use in 1988. [3][4] It was developed by Eli Lilly.
Combination with pyridoxine (vitamin B 6) decreases neurotoxicity but has been found to reduce the effectiveness of an altretamine/cisplatin regime. [8] MAO inhibitor can cause severe orthostatic hypotension when combined with altretamine; and cimetidine can increase its elimination half-life and toxicity.